Clinical trials: Non-Cirrhotic
Liver Circulation, Choledocholithiasis
Double Stent for Biliary Stones in Cirrhotic Patients
This prospective, single-center, interventional study enrolled 400 cirrhotic patients with large or complex common bile duct (CBD) stones that could not be removed during an initial Endoscopic Retrograde Cholangiopancreatography…
- Conditions
- Liver Circulation, Choledocholithiasis, Stent
- Trial name
- NCT07337291
- Testing
- Single 10 Fr Plastic Biliary Stent, Two 10 Fr Plastic Biliary Stent, Single 11.5 Fr Plastic Biliary Stent
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- National Liver Institute, Egypt
Cirrhosis
Carvedilol + VSL#3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.
Patients of cirrhosis will be enrolled who have large esophageal varices, which have never bled. After successful screening baseline hepatic venous pressure gradient (HVPG) will be measured.
- Trial name
- NCT01196481
- Testing
- Carvedilol+VSL#3, Endoscopic variceal ligation
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatitis B, Chronic
Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy
The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467
- Trial name
- NCT02631096
- Testing
- ARB-001467
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 36 people
- Sponsor
- Arbutus Biopharma Corporation
Esophageal Varices, Gastric Varices
Evaluation of Gastroesophageal Varices by Transnasal Endoscopy.
The study aims to evaluate the feasibility of transnasal endoscopy in patients with portal hypertension, cirrhotic and non-cirrhotic.
- Conditions
- Esophageal Varices, Gastric Varices, Hypertension Portal, Liver Cirrhosis
- Trial name
- NCT02767206
- Volunteers
- 50 people
- Sponsor
- Federal University of Minas Gerais
Gastric Cancer, Complication,Postoperative
The Model for End-Stage Liver Disease Sodium (MELD-Na) Score in Non-cirrhotic Patients With Gastric Cancer
Gastric cancer is the fifth most common cancer worldwide. Gastrectomy with lymphadenectomy is still the most effective treatment modality, depending on the stage and location.
- Conditions
- Gastric Cancer, Complication,Postoperative, Complications; Gastrointestinal, Postoperative, Morality
- Trial name
- NCT04791293
- Testing
- MELD-Na score
- Where
- Turkey (Türkiye)
- Volunteers
- 159 people
- Sponsor
- Istanbul Training and Research Hospital
Liver Cirrhosis, Portal Hypertension
Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients
To reduce portal pressure, the only recommended medication is nonselective beta blocker(NSBB). However, NSBB has some limitation to apply clinically because of poor response rate and compliance.
- Trial name
- RECOVER (NCT01897051)
- Testing
- Rifaximin + propranolol
- Where
- 2 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Yonsei University
Liver Cirrhosis With Diabetes
Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis
This study was a prospective, interventional, two-part pilot clinical study conducted over 3 months on cirrhotic patients with diabetes mellitus and diabetic neuropathy, evaluating the real-world applicability of selected…
- Trial name
- NCT07439536
- Testing
- Sitagliptin (Januvia), Sitagliptin (JANUVIA®), Duloxetine (60 mg) once daily
- Where
- Egypt
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University
NASH - Nonalcoholic Steatohepatitis
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
- Trial name
- NATiV3 (NCT04849728)
- Testing
- IVA337
- Where
- 459 sites in United States, Argentina and 22 more
- Volunteers
- 1,000 people
- Sponsor
- Inventiva Pharma
Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic
A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
A Phase III, Multicenter, open-labeded study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected Patients
- Conditions
- Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis, Treatment naïve
- Trial name
- NCT04155515
- Testing
- TG-2349, DAG181, Ribavirin
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
HCV
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
The purpose of this study is to assess the efficacy and safety of Ravidasvir in combination with Danoprevir/r and ribavirin(RBV) by sustain virologic response 12 (SVR12), in treatment-naive, non-cirrhotic, chronic hepatitis C…
- Trial name
- NCT03362814
- Testing
- Ravidasvir, Danoprevir, Ritonavir
- Where
- China
- Volunteers
- 425 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
The primary objectives of this study are to assess the safety of ABT-450/r/ABT-267 with and without ABT-333 coadministered with and without ribavirin (RBV) for 12 and 24 weeks in HCV GT1- or 4-infected participants with HIV-1…
- Conditions
- Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics
- Trial name
- TURQUOISE-I (NCT01939197)
- Testing
- ABT-450/r/ABT-267, ABT-333, ribavirin
- Volunteers
- 318 people
- Sponsor
- AbbVie
Hepatitis B, Chronic Hepatitis B
A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALN-HBV in healthy adult volunteers and patients with chronic hepatitis B virus (HBV) infection.
- Conditions
- Hepatitis B, Chronic Hepatitis B, Hepatitis B, Chronic, Hepatitis B Infection
- Trial name
- NCT02826018
- Testing
- ALN-HBV, Sterile Normal Saline (0.9% NaCl)
- Where
- 9 sites in Australia, Hong Kong and 4 more
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Hepatocellular Carcinoma, Non-cirrhotic Liver
Liver Transplantation for Hepatocellular Carcinoma Arising in Non-cirrhotic Liver: a Propensity Score-matched Retrospective Cohort Study of Two National Databases
Background: Majority of liver transplantation (LT) recipients for hepatocellular carcinoma (HCC) were concomitant with liver cirrhosis, while few researches focusing on recipients without cirrhosis.
- Trial name
- NCT06364839
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Xiao Xu
Hepatitis C
A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3
The purpose of this study is to determine if 8 weeks of Daclatasvir plus Sofosbuvir with or without Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients without advanced fibrosis or liver…
- Trial name
- NCT02551861
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 12 sites in Canada, France
- Sponsor
- Bristol-Myers Squibb
Cirrhosis, Muscle Cramp
Non-Pharmaceutical Intervention for Cirrhotic Cramps Reduction: The NICCles Trial
This clinical trial is evaluating the feasibility of using a non-pharmaceutical treatment to improve the symptoms and severity of muscle cramps in patients with cirrhosis.
- Conditions
- Cirrhosis, Muscle Cramp, Ascites
- Trial name
- NCT04650295
- Testing
- Household Remedy, Tap water
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Michigan
Liver Cirrhosis, Portal Hypertension
Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
Prospective, observational study to define precipitants and predictors of development of Acute-on-Chronic Liver Failure (ACLF) after surgical interventions, allowing to develop a risk stratification for elective procedures in…
- Conditions
- Liver Cirrhosis, Portal Hypertension, Surgery, Acute-On-Chronic Liver Failure
- Trial name
- PERSEVERE (NCT04578301)
- Testing
- No Intervention
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital, Bonn
Hepatitis B, HBV
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.
- Conditions
- Hepatitis B, HBV, Hepatitis B, Chronic
- Trial name
- NCT04059198
- Testing
- Inarigivir soproxil, Tenofovir alafenamide fumarate (TAF)
- Where
- 2 sites in Hong Kong
- Volunteers
- 5 people
- Sponsor
- F-star Therapeutics, Inc.
Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease
Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score
This retrospective cohort study evaluated the performance of non-invasive risk scores for predicting de novo hepatocellular carcinoma in adults with hepatitis C virus-related compensated advanced chronic liver disease who…
- Conditions
- Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease, Hepatocellular Carcinoma (HCC)
- Trial name
- HCV-aMAP (NCT07687758)
- Testing
- Non-invasive Risk Score Assessment
- Where
- Thailand
- Volunteers
- 571 people
- Sponsor
- Siriraj Hospital
Nonalcoholic Steatohepatitis
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M…
- Trial name
- FORTUNA (NCT05809934)
- Testing
- AZD2693
- Where
- 163 sites in United States, Argentina and 20 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
Vascular Liver Disease, Portal Vein Thrombosis
Vienna Vascular Liver Disease Study
The aim of this Register Trial is to systematically study the epidemiology, risk factors, liver function as well prognosis of patients with vascular liver diseases.
- Conditions
- Vascular Liver Disease, Portal Vein Thrombosis, Budd-Chiari Syndrome, Non-Cirrhotic Portal Hypertension
- Trial name
- VALID (NCT03541057)
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna